Trade Mark Journal No.2025/028 11 July 2025

UK00004228867 3 July 2025 (5,42)

SANDPIPER THERAPEUTICS

International priority date claimed: 7 January 2025 (United States of America) (98942955)

Class 5: Pharmaceutical and medical preparations; pharmaceutical preparations for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; biological preparations for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; therapeutic pharmaceuticals for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; biological therapies for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases.
Class 42: Product research, design and development services; pharmaceutical research, design and development services; scientific and medical research; research and development in the field of therapeutics; drug discovery services; project management in the field of pharmaceutical development; research and development in the field of small molecule drug discovery for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; pharmaceutical products development in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; scientific research for medical purposes in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; pharmaceutical research and development services in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; research and development of therapeutics for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; drug discovery services in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; research and development in the field of precision medicine for use in oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; medical and scientific research in the fields of oncology, immunology, cardiometabolic diseases, and cardiovascular diseases; information, consultancy and advisory services in relation to all of the above.

Sandpiper Therapeutics, Inc.

Representative: CMS Cameron McKenna Nabarro Olswang LLP